Abstract
Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Current Pharmaceutical Design
Title: 5-Hydroxytryptamine (5-HT) Receptor Ligands
Volume: 13 Issue: 25
Author(s): Sean L Kitson
Affiliation:
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Abstract: Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Export Options
About this article
Cite this article as:
Kitson L Sean, 5-Hydroxytryptamine (5-HT) Receptor Ligands, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663000
DOI https://dx.doi.org/10.2174/138161207781663000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Skeletal Muscle Dysfunction with Aging
Current Aging Science Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Relevance of Cytochrome P450 Polymorphisms in the Treatment of Helicobacter pylori Infection and Gastroesophageal Reflux Disease
Current Pharmacogenomics Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Decreased Myelinated Fibers in the Hippocampal Dentate Gyrus of the Tg2576 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot Topic: Clinical Relevance of Indoleamine 2,3-Dioxygenase (Guest Editor: Dietmar Fuchs) ]
Current Drug Metabolism Editorial [Hot Topic: The Evolving Challenges in Pediatric HIV Management (Guest Editors: Emanuele Pontali and Raffaella Rosso)]
Current Pediatric Reviews From the Multifactorial Nature of Alzheimer`s Disease to Multitarget Therapy: The Contribution of the Translational Approach
Current Topics in Medicinal Chemistry Schwann Cell Transplantation for CNS Repair
Current Medicinal Chemistry Editorial (Thematic Issue: Neuroprotective Effects of Li - It is Elementary)
Current Alzheimer Research The Endocannabinoid/Endovanilloid System and Depression
Current Neuropharmacology Current Trends in the Development of New Antidepressants
Current Medicinal Chemistry Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage
Current Neurovascular Research FDA-approved Drugs Selected Using Virtual Screening Bind Specifically to G-quadruplex DNA
Current Pharmaceutical Design Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Current Alzheimer Research Matrix Factorization-based Improved Classification of Gene Expression Data
Recent Advances in Computer Science and Communications Complementary and Alternative Medical Therapies in Fibromyalgia
Current Pharmaceutical Design Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research